Literature DB >> 16014960

Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.

Zhu-Nan Li1, Scott N Mueller, Ling Ye, Zhigao Bu, Chinglai Yang, Rafi Ahmed, David A Steinhauer.   

Abstract

Large polypeptides of the Bacillus anthracis protective antigen (PA) were inserted into an influenza A virus hemagglutinin glycoprotein (HA), and the chimeric proteins were functionally characterized and incorporated into infectious influenza viruses. PA domain 1', the region responsible for binding to the other toxin components, the lethal factor and edema factor, and domain 4, the receptor binding domain (RBD), were inserted at the C-terminal flank of the HA signal peptide and incorporated into the HA1 subunit of HA. The chimeric proteins, designated as LEF/HA (90 amino acid insertion) and RBD/HA (140 amino acid insertion), were initially analyzed following expression using recombinant vaccinia viruses. Both chimeric proteins were shown to display functional phenotypes similar to that of the wild-type HA. They transport to the cell surface, can be cleaved into the HA1 and HA2 subunits by trypsin to activate membrane fusion potential, are able to undergo the low-pH-induced conformational changes required for fusion, and are capable of inducing the fusion process. We were also able to generate recombinant influenza viruses containing the chimeric RBD/HA and LEF/HA genes, and the inserted PA domains were maintained in the HA gene segments following several passages in MDCK cells or embryonated chicken eggs. Furthermore, DNA immunization of mice with plasmids that express the chimeric RBD/HA and LEF/HA proteins, and the recombinant viruses containing them, induced antibody responses against both the HA and PA components of the protein. These approaches may provide useful tools for vaccines against anthrax and other diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014960      PMCID: PMC1181555          DOI: 10.1128/JVI.79.15.10003-10012.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?

Authors:  Gabriele Neumann; Michael A Whitt; Yoshihiro Kawaoka
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

2.  Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization.

Authors:  Shihui Liu; Stephen H Leppla
Journal:  J Biol Chem       Date:  2002-12-04       Impact factor: 5.157

3.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 4.  Generation of influenza A virus from cloned cDNAs--historical perspective and outlook for the new millenium.

Authors:  Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Rev Med Virol       Date:  2002 Jan-Feb       Impact factor: 6.989

5.  Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants.

Authors:  Yurie Nakaya; Hongyong Zheng; Adolfo García-Sastre
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

6.  X-ray structures of H5 avian and H9 swine influenza virus hemagglutinins bound to avian and human receptor analogs.

Authors:  Y Ha; D J Stevens; J J Skehel; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

7.  H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes.

Authors:  Ya Ha; David J Stevens; John J Skehel; Don C Wiley
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

8.  Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity.

Authors:  Jennifer A Maynard; Catharina B M Maassen; Stephen H Leppla; Kathleen Brasky; Jean L Patterson; Brent L Iverson; George Georgiou
Journal:  Nat Biotechnol       Date:  2002-06       Impact factor: 54.908

9.  A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.

Authors:  Helen C Flick-Smith; Nicola J Walker; Paula Gibson; Helen Bullifent; Sarah Hayward; Julie Miller; Richard W Titball; E Diane Williamson
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

10.  Selective incorporation of influenza virus RNA segments into virions.

Authors:  Yutaka Fujii; Hideo Goto; Tokiko Watanabe; Tetsuya Yoshida; Yoshihiro Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

View more
  25 in total

1.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  A method for the unbiased quantification of reassortment in segmented viruses.

Authors:  Megan R Hockman; Kara L Phipps; Katie E Holmes; Anice C Lowen
Journal:  J Virol Methods       Date:  2020-04-28       Impact factor: 2.014

3.  Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

Authors:  Fu-Shi Quan; Chunzi Huang; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Min-Kyoung Cho; Young-Man Kwon; Jong Seok Lee; Richard K Plemper; Sang-Moo Kang
Journal:  Virology       Date:  2014-12-30       Impact factor: 3.616

5.  Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Jong Seok Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-12-13       Impact factor: 5.970

6.  Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Authors:  Min-Chul Kim; Yu-Na Lee; Yu-Jin Kim; Hyo-Jick Choi; Ki-Hye Kim; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2017-10-26       Impact factor: 5.970

7.  The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus.

Authors:  Benjamin O Fulton; Weina Sun; Nicholas S Heaton; Peter Palese
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

8.  A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.

Authors:  Byron E E Martina; Petra van den Doel; Penelope Koraka; Geert van Amerongen; Gunther Spohn; Bart L Haagmans; Lisette B V Provacia; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

9.  Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin.

Authors:  Bruno Garulli; Giuseppina Di Mario; Ester Sciaraffia; Yoshihiro Kawaoka; Maria R Castrucci
Journal:  J Biomed Biotechnol       Date:  2011-10-05

10.  Influenza virus reassortment occurs with high frequency in the absence of segment mismatch.

Authors:  Nicolle Marshall; Lalita Priyamvada; Zachary Ende; John Steel; Anice C Lowen
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.